Blueprint Medicines (BPMC) Stock Statistics & Valuation Metrics

Blueprint Medicines has a market cap or net worth of $5.24B. The enterprise value is $5.66B.

Blueprint Medicines has 63.91M shares outstanding. The number of shares has decreased by -2.65% in one year.

Blueprint Medicines’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -22.12%.

The current PE Ratio of Blueprint Medicines is -81.72. Blueprint Medicines’s PEG ratio is 0.94.

In the last 12 months, Blueprint Medicines had revenue of $508.82M and earned -$67.09M in profits. Earnings per share was -$1.03.

In the last 12 months, operating cash flow was -$192.59M and capital expenditures -$4.63M, giving a free cash flow of -$197.22M billion.

Blueprint Medicines pays an annual dividend of , resulting in a dividend yield of

Blueprint Medicines upcoming earnings date is May 1, 2025, Before Open.

Blueprint Medicines as a current ratio of 2.85, with Debt / Equity ratio of 0.42

In the past 12 months, Blueprint Medicines has paid $1.23M in taxes.

Blueprint Medicines EV to EBITDA ratio is -25.97, with an EV/FCF ratio of -27.92.

Blueprint Medicines has $615.49M in cash and marketable securities with $469.11M in debt, giving a net cash position of -$146.38M billion.

Gross margin is 96.04%, with operating margin of -41.67%, and net profit margin of -13.19%.

The average price target for Blueprint Medicines is $130.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy